October 19, 2010

Johnson & Johnson Reports 2010 Third-Quarter Results:

Sales of $15.0 Billion Decreased 0.7% Versus 2009 Third-Quarter; EPS of $1.23 increased 2.5% Versus 2009 Third-Quarter

NEW BRUNSWICK, N.J., Oct 19, 2010 /PRNewswire via COMTEX News Network/ -- Johnson & Johnson (NYSE: JNJ) today announced sales of $15.0 billion for the third quarter of 2010, a decrease of 0.7% as compared to the third quarter of 2009. Operational results increased 0.1% and the negative impact of currency was 0.8%. Domestic sales declined 2.5%, while international sales increased 1.1%, reflecting operational growth of 2.6% and a negative currency impact of 1.5%.

Net earnings and diluted earnings per share for the third quarter of 2010 were $3.4 billion and $1.23, respectively, representing increases of 2.2% and 2.5%, as compared to the same period in 2009.

The Company raised its earnings guidance for full-year 2010 to $4.70 - $4.80 per share, reflecting recent currency exchange rates. The Company's guidance excludes the impact of special items.

"We continue to deliver solid earnings while investing in our future through complementary strategic partnerships and acquisitions," said William C. Weldon, Chairman and Chief Executive Officer. "Our pharmaceutical business has returned to growth this year and we continue to advance our pipeline with promising clinical data in key therapeutic areas. We are pleased with the strong performance of newly launched products in both our pharmaceutical and medical device and diagnostics businesses."

Worldwide Consumer sales of $3.6 billion for the third quarter represented a decrease of 10.6% versus the prior year consisting of an operational decline of 10.2% and a negative impact from currency of 0.4%. Domestic sales decreased 24.5%; international sales decreased 0.3%, which reflected an operational increase of 0.4% and a negative currency impact of 0.7%.

Positive contributors to operational results were Dabao skin care products, baby care products, and international sales of anti-smoking aids. Sales were significantly impacted by the previously announced recalls of certain over-the-counter medicines and the suspension of manufacturing at the McNeil Consumer Healthcare Fort Washington, Pa., facility as well as the currency devaluation in Venezuela. With respect to the ongoing remediation actions at the Fort Washington facility, Mr. Weldon stated, "We have made considerable progress, and are working diligently to reopen what will be a state of the art facility. Working across our production network, we have begun restoring the supply of some of the impacted children's medicines, which will increase in the coming months."

Worldwide Pharmaceutical sales of $5.5 billion for the third quarter represented an increase of 4.7% versus the prior year with operational growth of 5.9% and a negative impact from currency of 1.2%. Domestic sales increased 6.9%; international sales increased 2.0%, which reflected an operational increase of 4.6% and a negative currency impact of 2.6%.

Several products had strong operational growth including sales of REMICADE(R) (infliximab), a biologic approved for the treatment of a number of immune mediated inflammatory diseases; PREZISTA(R) (darunavir), a treatment for HIV; international sales of RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Treatment, an antipsychotic medication; INTELENCE(R) (etravirine), a next generation non-nucleoside reverse transcriptase inhibitor for HIV; and VELCADE(R) (bortezomib), a treatment for multiple myeloma.

Sales growth also includes the strong performance of newly launched products including STELARA(TM) (ustekinumab), a biologic approved for the treatment of moderate to severe plaque psoriasis; SIMPONI(TM) (golimumab), a biologic approved to treat adults with moderate to severe rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis; and INVEGA(R) SUSTENNA(TM) (paliperidone palmitate), an extended-release injectable suspension for the acute and maintenance treatment of schizophrenia in adults.

During the quarter, the Company submitted new drug applications for TMC 278, a once-daily investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV, to the U.S. Food and Drug Administration and the European Medicines Agency. A supplemental Biologics License Application was also filed in the U.S. to expand the SIMPONI(R) (golimumab) label in rheumatoid arthritis (RA) to include inhibiting the progression of structural damage in the treatment of moderately to severely active RA.

In October, the Company entered into an agreement to acquire all outstanding equity of Crucell N.V. not already owned by the Company for approximately euro 1.75 billion in a cash tender offer. Crucell is a global biopharmaceutical company focused on the research & development, production and marketing of vaccines and antibodies against infectious disease worldwide.

Worldwide Medical Devices and Diagnostics sales of $5.9 billion for the third quarter represented an increase of 1.3% versus the prior year consisting of an operational increase of 1.9% and a negative currency impact of 0.6%. Domestic sales increased 1.2%; international sales increased 1.4%, which reflected an operational increase of 2.6% and a negative currency impact of 1.2%.

Primary contributors to operational growth included Ethicon's surgical care products; Ethicon Endo-Surgery's minimally invasive and advanced sterilization products; Biosense Webster's electrophysiology business; and DePuy's orthopaedic joint reconstruction business. This growth was partially offset by lower sales in the Cordis franchise, reflecting continued competition in the drug-eluting stent market.

During the quarter, the Company completed the acquisition of Micrus Endovascular, a global developer and manufacturer of minimally invasive devices for the treatment of hemorrhagic and ischemic stroke.

About Johnson & Johnson

Caring for the world, one person at a time... inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 114,000 employees at more than 250 Johnson & Johnson companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

NOTE TO INVESTORS

Johnson & Johnson will conduct a meeting with financial analysts to discuss this news release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the meeting for investors and other interested parties may be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com. A replay and podcast will be available approximately two hours after the live webcast by visiting www.investor.jnj.com.

Copies of the financial schedules accompanying this press release are available at www.investor.jnj.com/historical-sales.cfm. These schedules include supplementary sales data, a condensed consolidated statement of earnings, and sales of key products/franchises. Additional information on Johnson & Johnson, including a pharmaceutical pipeline of selected compounds in late stage development and medical devices and diagnostics pipeline of selected products, can be found on the Company's website at www.jnj.com

(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Johnson & Johnson's expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 3, 2010. Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statements as a result of new information or future events or developments.)

    Johnson & Johnson and Subsidiaries
    ----------------------------------
    Supplementary Sales Data



    (Unaudited;
     Dollars in
     Millions)                       THIRD QUARTER
    -----------                      -------------
                                                 Percent Change
                                                 --------------
                         2010   2009    Total         Operations  Currency
                         ----   ----    -----         ----------  --------
    Sales to
     customers by
     segment of
     business

    Consumer
        U.S.           $1,277  1,691     (24.5)%           (24.5)        -
        International   2,290  2,298       (0.3)             0.4      (0.7)
        -------------   -----  -----       ----              ---      ----
                        3,567  3,989      (10.6)           (10.2)     (0.4)
                        =====  =====      =====            =====      ====

    Pharmaceutical
        U.S.            3,054  2,857        6.9              6.9         -
        International   2,441  2,392        2.0              4.6      (2.6)
        -------------   -----  -----        ---              ---      ----
                        5,495  5,249        4.7              5.9      (1.2)
                        =====  =====        ===              ===      ====

    Med Devices &
     Diagnostics
        U.S.            2,800  2,766        1.2              1.2         -
        International   3,120  3,077        1.4              2.6      (1.2)
        -------------   -----  -----        ---              ---      ----
                        5,920  5,843        1.3              1.9      (0.6)
                        =====  =====        ===              ===      ====

    U.S.                7,131  7,314       (2.5)            (2.5)        -
    International       7,851  7,767        1.1              2.6      (1.5)
    -------------       -----  -----        ---              ---      ----
    Worldwide         $14,982 15,081      (0.7)%             0.1      (0.8)
    =========         ======= ======      =====              ===      ====



    (Unaudited; Dollars in
     Millions)                            NINE MONTHS
    ----------------------                -----------
                                                     Percent Change
                                                     --------------
                              2010   2009   Total         Operations  Currency
                              ----   ----   -----         ----------  --------
    Sales to customers by
     segment of business

    Consumer
        U.S.                $4,300  5,125    (16.1)%           (16.1)        -
        International        6,680  6,429       3.9              0.5       3.4
        -------------        -----  -----       ---              ---       ---
                            10,980 11,554      (5.0)            (6.9)      1.9
                            ====== ======      ====             ====       ===

    Pharmaceutical
        U.S.                 9,370  9,703      (3.4)            (3.4)        -
        International        7,316  6,824       7.2              5.3       1.9
        -------------        -----  -----       ---              ---       ---
                            16,686 16,527       1.0              0.2       0.8
                            ====== ======       ===              ===       ===

    Med Devices &
     Diagnostics
        U.S.                 8,551  8,194       4.4              4.4         -
        International        9,726  9,071       7.2              4.5       2.7
        -------------        -----  -----       ---              ---       ---
                            18,277 17,265       5.9              4.5       1.4
                            ====== ======       ===              ===       ===

    U.S.                    22,221 23,022      (3.5)            (3.5)        -
    International           23,722 22,324       6.3              3.7       2.6
    -------------           ------ ------       ---              ---       ---
    Worldwide              $45,943 45,346       1.3%             0.0       1.3
    =========              ======= ======       ===              ===       ===


    Johnson & Johnson and Subsidiaries
    ----------------------------------
    Supplementary Sales Data



    (Unaudited;
     Dollars in
     Millions)                      THIRD QUARTER
                                    -------------
                                                 Percent Change
                                                 --------------
                        2010   2009  Total         Operations   Currency
                        ----   ----  -----         ----------   --------
    Sales to
     customers by
     geographic area

    U.S.              $7,131  7,314   (2.5)%             (2.5)         -
    ----              ------  -----   -----              ----        ---

    Europe             3,629  3,879    (6.4)              1.8       (8.2)
    Western
     Hemisphere
     excluding U.S.    1,424  1,338     6.4               1.7        4.7
    Asia-Pacific,
     Africa            2,798  2,550     9.7               4.1        5.6
    International      7,851  7,767     1.1               2.6       (1.5)
    -------------      -----  -----     ---               ---       ----

    Worldwide        $14,982 15,081   (0.7)%              0.1       (0.8)
    =========        ======= ======   =====               ===       ====



    (Unaudited; Dollars
     in Millions)                     NINE MONTHS
                                      -----------
                                                  Percent Change
                                                  --------------
                           2010   2009      Total        Operations  Currency
                           ----   ----      -----        ----------  --------
    Sales to customers
     by geographic area

    U.S.                $22,221 23,022       (3.5)%            (3.5)        -
    ----                ------- ------       -----             ----       ---

    Europe               11,563 11,522         0.4              2.6      (2.2)
    Western Hemisphere
     excluding U.S.       4,079  3,615        12.8              2.5      10.3
    Asia-Pacific,
     Africa               8,080  7,187        12.4              5.9       6.5

    International        23,722 22,324         6.3              3.7       2.6
    -------------        ------ ------         ---              ---       ---

    Worldwide           $45,943 45,346         1.3%             0.0       1.3
    =========           ======= ======         ===              ===       ===


    Johnson & Johnson and Subsidiaries
    ----------------------------------
    Condensed Consolidated Statement of Earnings



    (Unaudited; in
     Millions Except
     Per Share
     Figures)                           THIRD QUARTER
    ----------------                    -------------

                                  2010                   2009     Percent
                                  ----                   ----
                               Percent                Percent    Increase
                                    to                     to
                       Amount    Sales    Amount        Sales  (Decrease)
                       ------   ------    ------       ------  ----------
    Sales to
     customers        $14,982    100.0   $15,081        100.0        (0.7)
    ----------        -------    -----   -------        -----        ----
    Cost of products
     sold               4,594     30.7     4,434         29.4         3.6
    Selling,
     marketing and
     administrative
     expenses           4,709     31.4     4,767         31.6        (1.2)
    Research expense    1,657     11.1     1,617         10.7         2.5
    Interest
     (income)expense,
     net                   95      0.6       114          0.7
    Other
     (income)expense,
     net                 (292)    (2.0)      (96)        (0.6)
    -----------------    ----     ----       ---         ----
    Earnings before
     provision for
     taxes on income    4,219     28.2     4,245         28.2        (0.6)
    Provision for
     taxes on income      802      5.4       900          6.0       (10.9)
    ----------------      ---      ---       ---          ---       -----
    Net earnings       $3,417     22.8    $3,345         22.2         2.2
    ============       ======     ====    ======         ====         ===

    Net earnings per
     share
     (Diluted)          $1.23              $1.20                      2.5

    Average shares
     outstanding
     (Diluted)        2,786.4            2,793.0

    Effective tax
     rate                19.0%              21.2%


    Johnson & Johnson and Subsidiaries
    ----------------------------------
    Condensed Consolidated Statement of Earnings



    (Unaudited; in Millions Except Per Share
     Figures)                                             NINE MONTHS
    ----------------------------------------              -----------

                                                                        2010
                                                                        ----
                                                                     Percent
                                                      Amount        to Sales
                                                      ------        --------
    Sales to customers                               $45,943           100.0
    ------------------                               -------           -----
    Cost of products sold                             13,752            29.9
    Selling, marketing and administrative
     expenses                                         14,244            31.0
    Research expense                                   4,862            10.6
    Interest (income)expense, net                        234             0.5
    Other (income)expense, net                        (1,868)           (4.0)
    --------------------------                        ------            ----
    Earnings before provision for taxes on
     income                                           14,719            32.0
    Provision for taxes on income                      3,327             7.2
    -----------------------------                      -----             ---
    Net earnings                                     $11,392            24.8
    ============                                     =======            ====

    Net earnings per share  (Diluted)                  $4.08

    Average shares outstanding  (Diluted)            2,792.0

    Effective tax rate                                  22.6%


    Adjusted earnings before provision for
     taxes and net earnings
         Earnings before provision for taxes on
          income                                     $13,379    (1)     29.1
         Net earnings                                $10,415    (1)     22.7
         Net earnings per share  (Diluted)             $3.73    (1)
         Effective tax rate                             22.2%
         ------------------                             ----



    (Unaudited; in Millions Except
     Per Share Figures)                           NINE MONTHS
    ------------------------------                -----------

                                                             2009     Percent
                                                             ----
                                                          Percent    Increase
                                            Amount       to Sales  (Decrease)
                                            ------       --------  ----------
    Sales to customers                     $45,346          100.0         1.3
    ------------------                     -------          -----         ---
    Cost of products sold                   13,135           29.0         4.7
    Selling, marketing and
     administrative expenses                14,172           31.3         0.5
    Research expense                         4,773           10.5         1.9
    Interest (income)expense, net              280            0.6
    Other (income)expense, net                (165)          (0.4)
    --------------------------                ----           ----
    Earnings before provision for
     taxes on income                        13,151           29.0        11.9
    Provision for taxes on income            3,091            6.8         7.6
    -----------------------------            -----            ---         ---
    Net earnings                           $10,060           22.2        13.2
    ============                           =======           ====        ====

    Net earnings per share  (Diluted)        $3.61                       13.0

    Average shares outstanding
     (Diluted)                             2,787.9

    Effective tax rate                        23.5%


    Adjusted earnings before
     provision for taxes and net
     earnings
         Earnings before provision for
          taxes on income                  $13,151           29.0         1.7
         Net earnings                      $10,060           22.2         3.5
         Net earnings per share  (Diluted)   $3.61                        3.3
         Effective tax rate                   23.5%
         ------------------                   ----



                        REPORTED SALES vs. PRIOR PERIOD ($MM)
                        -------------------------------------
                                         THIRD QUARTER
                                         -------------
                                                     % Change
                                                     --------
                                                     Operational
                        2010     2009   Reported          (1)      Currency
                        ----     ----   --------   --------------  --------
    CONSUMER
     SEGMENT (2)
    ------------
    SKIN CARE
    ---------
    US                   311      370      -15.9%           -15.9%        -
    Intl                 489      472        3.6%             3.7%     -0.1%
    WW                   800      842       -5.0%            -4.9%     -0.1%
    BABY CARE
    ---------
    US                   104      102        2.0%             2.0%        -
    Intl                 462      442        4.5%             3.6%      0.9%
    WW                   566      544        4.0%             3.3%      0.7%
    ORAL CARE
    ---------
    US                   164      187      -12.3%           -12.3%        -
    Intl                 220      223       -1.3%            -2.2%      0.9%
    WW                   384      410       -6.3%            -6.8%      0.5%
    OTC/
     NUTRITIONALS
    -------------
    US                   438      732      -40.2%           -40.2%        -
    Intl                 671      666        0.8%             3.5%     -2.7%
    WW                 1,109    1,398      -20.7%           -19.4%     -1.3%
    WOMEN'S HEALTH
    --------------
    US                   121      142      -14.8%           -14.8%        -
    Intl                 338      360       -6.1%            -5.1%     -1.0%
    WW                   459      502       -8.6%            -7.9%     -0.7%
    WOUND CARE/
     OTHER
    -----------
    US                   139      158      -12.0%           -12.0%        -
    Intl                 110      135      -18.5%           -18.5%      0.0%
    WW                   249      293      -15.0%           -15.0%      0.0%
    TOTAL CONSUMER
    --------------
    US                 1,277    1,691      -24.5%           -24.5%        -
    Intl               2,290    2,298       -0.3%             0.4%     -0.7%
    WW                 3,567    3,989      -10.6%           -10.2%     -0.4%



    See footnotes
     on last page



    PHARMACEUTICAL
     SEGMENT  (2)
     (6)
    ------------------
    ACIPHEX/PARIET
    --------------
    US                   116      131      -11.5%           -11.5%        -
    Intl                 124      130       -4.6%             0.8%     -5.4%
    WW                   240      261       -8.0%            -5.3%     -2.7%
    CONCERTA
    --------
    US                   214      205        4.4%             4.4%        -
    Intl                  85       79        7.6%             9.3%     -1.7%
    WW                   299      284        5.3%             5.8%     -0.5%
    DURAGESIC/
     FENTANYL
     TRANSDERMAL
    ------------
    US                    42       38       10.5%            10.5%        -
    Intl                 142      168      -15.5%           -14.2%     -1.3%
    WW                   184      206      -10.7%            -9.6%     -1.1%
    LEVAQUIN/
     FLOXIN
    ---------
    US                   274      294       -6.8%            -6.8%        -
    Intl                  12       17      -29.4%           -31.5%      2.1%
    WW                   286      311       -8.0%            -8.1%      0.1%
    PREZISTA
    --------
    US                   102       78       30.8%            30.8%        -
    Intl                 128       73       75.3%            82.7%     -7.4%
    WW                   230      151       52.3%            55.9%     -3.6%
    PROCRIT/EPREX
    -------------
    US                   204      299      -31.8%           -31.8%        -
    Intl                 202      243      -16.9%           -11.9%     -5.0%
    WW                   406      542      -25.1%           -22.9%     -2.2%
    REMICADE
    --------
    US                   857      822        4.3%             4.3%        -
    US Exports (3)       365      208       75.5%            75.5%        -
    Intl                   7        6       16.7%            16.7%        -
    WW                 1,229    1,036       18.6%            18.6%        -
    RISPERDAL/
     RISPERIDONE
    ------------
    US                    (2)      35     -105.7%          -105.7%        -
    Intl                 123      157      -21.7%           -22.8%      1.1%
    WW                   121      192      -37.0%           -37.9%      0.9%
    RISPERDAL
     CONSTA
    ---------
    US                   108      129      -16.3%           -16.3%        -
    Intl                 270      224       20.5%            26.6%     -6.1%
    WW                   378      353        7.1%            11.0%     -3.9%
    TOPAMAX
    -------
    US                    46       72      -36.1%           -36.1%        -
    Intl                  81      103      -21.4%           -18.1%     -3.3%
    WW                   127      175      -27.4%           -25.4%     -2.0%
    VELCADE
    -------
    US                     -        -          -                -         -
    Intl                 246      231        6.5%            10.1%     -3.6%
    WW                   246      231        6.5%            10.1%     -3.6%
    OTHER
    -----
    US                   728      546       33.3%            33.3%        -
    Intl               1,021      961        6.2%             7.4%     -1.2%
    WW                 1,749    1,507       16.1%            16.9%     -0.8%
    TOTAL
     PHARMACEUTICAL
    ---------------
    US                 3,054    2,857        6.9%             6.9%        -
    Intl               2,441    2,392        2.0%             4.6%     -2.6%
    WW                 5,495    5,249        4.7%             5.9%     -1.2%
                         ---      ---        ---              ---      ----
    MAJOR NEW
     PHARM
     PRODUCTS (4)
    -------------
    INVEGA
    ------
    US                    63       61        3.3%             3.3%        -
    Intl                  35       36       -2.8%             1.7%     -4.5%
    WW                    98       97        1.0%             2.7%     -1.7%


    See footnotes
     on last page



    MEDICAL
     DEVICES AND
     DIAGNOSTICS
     (2)
    ------------
    CORDIS (5)
    ---------
    US                   246      233        5.6%             5.6%        -
    Intl                 350      407      -14.0%           -13.5%     -0.5%
    WW                   596      640       -6.9%            -6.6%     -0.3%
    DEPUY
    -----
    US                   748      740        1.1%             1.1%        -
    Intl                 561      544        3.1%             4.8%     -1.7%
    WW                 1,309    1,284        1.9%             2.6%     -0.7%
    DIABETES CARE
    -------------
    US                   338      332        1.8%             1.8%        -
    Intl                 275      302       -8.9%             0.2%     -9.1%
    WW                   613      634       -3.3%             1.0%     -4.3%
    ETHICON
    -------
    US                   480      439        9.3%             9.3%        -
    Intl                 592      580        2.1%             3.4%     -1.3%
    WW                 1,072    1,019        5.2%             6.0%     -0.8%
    ETHICON ENDO-
     SURGERY
    -------------
    US                   484      499       -3.0%            -3.0%        -
    Intl                 653      607        7.6%             8.4%     -0.8%
    WW                 1,137    1,106        2.8%             3.3%     -0.5%
    ORTHO-
     CLINICAL
     DIAGNOSTICS
    ------------
    US                   263      285       -7.7%            -7.7%        -
    Intl                 235      216        8.8%             9.2%     -0.4%
    WW                   498      501       -0.6%            -0.4%     -0.2%
    VISION CARE
    -----------
    US                   241      238        1.3%             1.3%        -
    Intl                 454      421        7.8%             4.0%      3.8%
    WW                   695      659        5.5%             3.1%      2.4%
    TOTAL MEDICAL
     DEVICES AND
     DIAGNOSTICS
    -------------
    US                 2,800    2,766        1.2%             1.2%        -
    Intl               3,120    3,077        1.4%             2.6%     -1.2%
    WW                 5,920    5,843        1.3%             1.9%     -0.6%





                         REPORTED SALES vs. PRIOR PERIOD ($MM)
                         -------------------------------------
                                           NINE MONTHS
                                           -----------
                                                       % Change
                                                       --------
                                                       Operational
                          2010     2009   Reported          (1)      Currency
                          ----     ----   --------   --------------  --------
    CONSUMER
     SEGMENT (2)
    ------------
    SKIN CARE
    ---------
    US                   1,185    1,204       -1.6%            -1.6%        -
    Intl                 1,378    1,313        5.0%             2.0%      3.0%
    WW                   2,563    2,517        1.8%             0.2%      1.6%
    BABY CARE
    ---------
    US                     306      308       -0.6%            -0.6%        -
    Intl                 1,326    1,233        7.5%             3.3%      4.2%
    WW                   1,632    1,541        5.9%             2.5%      3.4%
    ORAL CARE
    ---------
    US                     486      549      -11.5%           -11.5%        -
    Intl                   651      612        6.4%             1.3%      5.1%
    WW                   1,137    1,161       -2.1%            -4.8%      2.7%
    OTC/
     NUTRITIONALS
    -------------
    US                   1,472    2,137      -31.1%           -31.1%        -
    Intl                 1,985    1,919        3.4%             0.7%      2.7%
    WW                   3,457    4,056      -14.8%           -16.1%      1.3%
    WOMEN'S
     HEALTH
    -------
    US                     404      443       -8.8%            -8.8%        -
    Intl                   990      963        2.8%            -0.4%      3.2%
    WW                   1,394    1,406       -0.9%            -3.1%      2.2%
    WOUND CARE/
     OTHER
    -----------
    US                     447      484       -7.6%            -7.6%        -
    Intl                   350      389      -10.0%           -13.9%      3.9%
    WW                     797      873       -8.7%           -10.4%      1.7%
    TOTAL
     CONSUMER
    ---------
    US                   4,300    5,125      -16.1%           -16.1%        -
    Intl                 6,680    6,429        3.9%             0.5%      3.4%
    WW                  10,980   11,554       -5.0%            -6.9%      1.9%



    See footnotes
     on last page



     PHARMACEUTICAL
     SEGMENT  (2)
     (6)
    -------------------
    ACIPHEX/
     PARIET
    --------
    US                     356      397      -10.3%           -10.3%        -
    Intl                   398      387        2.8%             2.0%      0.8%
    WW                     754      784       -3.8%            -4.2%      0.4%
    CONCERTA
    --------
    US                     668      707       -5.5%            -5.5%        -
    Intl                   283      238       18.9%            14.3%      4.6%
    WW                     951      945        0.6%            -0.6%      1.2%
    DURAGESIC/
     FENTANYL
     TRANSDERMAL
    ------------
    US                     117      163      -28.2%           -28.2%        -
    Intl                   435      492      -11.6%           -13.4%      1.8%
    WW                     552      655      -15.7%           -17.1%      1.4%
    LEVAQUIN/
     FLOXIN
    ---------
    US                     926    1,045      -11.4%           -11.4%        -
    Intl                    31       53      -41.5%           -44.2%      2.7%
    WW                     957    1,098      -12.8%           -12.9%      0.1%
    PREZISTA
    --------
    US                     290      215       34.9%            34.9%        -
    Intl                   331      198       67.2%            66.8%      0.4%
    WW                     621      413       50.4%            50.2%      0.2%
    PROCRIT/EPREX
    -------------
    US                     800      950      -15.8%           -15.8%        -
    Intl                   655      719       -8.9%            -9.2%      0.3%
    WW                   1,455    1,669      -12.8%           -12.9%      0.1%
    REMICADE
    --------
    US                   2,420    2,330        3.9%             3.9%        -
    US Exports
     (3)                 1,106      821       34.7%            34.7%        -
    Intl                    19       15       26.7%            26.7%      0.0%
    WW                   3,545    3,166       12.0%            12.0%        -
    RISPERDAL/
     RISPERIDONE
    ------------
    US                     (14)     223     -106.3%          -106.3%        -
    Intl                   390      483      -19.3%           -21.7%      2.4%
    WW                     376      706      -46.7%           -48.4%      1.7%
    RISPERDAL
     CONSTA
    ---------
    US                     340      386      -11.9%           -11.9%        -
    Intl                   772      640       20.6%            20.3%      0.3%
    WW                   1,112    1,026        8.4%             8.2%      0.2%
    TOPAMAX
    -------
    US                     162      642      -74.8%           -74.8%        -
    Intl                   255      317      -19.6%           -20.5%      0.9%
    WW                     417      959      -56.5%           -56.8%      0.3%
    VELCADE
    -------
    US                       -        -        0.0%             0.0%        -
    Intl                   793      652       21.6%            20.3%      1.3%
    WW                     793      652       21.6%            20.3%      1.3%
    OTHER
    -----
    US                   2,199    1,824       20.6%            20.6%        -
    Intl                 2,954    2,630       12.3%             9.4%      2.9%
    WW                   5,153    4,454       15.7%            14.0%      1.7%
    TOTAL
     PHARMACEUTICAL
    ---------------
    US                   9,370    9,703       -3.4%            -3.4%        -
    Intl                 7,316    6,824        7.2%             5.3%      1.9%
    WW                  16,686   16,527        1.0%             0.2%      0.8%
                          ----     ----        ---              ---       ---
    MAJOR NEW
     PHARM
     PRODUCTS (4)
    -------------
    INVEGA
    ------
    US                     200      194        3.1%             3.1%        -
    Intl                   108       93       16.1%            15.2%      0.9%
    WW                     308      287        7.3%             7.0%      0.3%



    See footnotes
     on last page



    MEDICAL
     DEVICES AND
     DIAGNOSTICS
      (2)
    ------------
    CORDIS (5)
    ---------
    US                     762      731        4.2%             4.2%        -
    Intl                 1,161    1,251       -7.2%            -9.4%      2.2%
    WW                   1,923    1,982       -3.0%            -4.4%      1.4%
    DEPUY
    -----
    US                   2,338    2,268        3.1%             3.1%        -
    Intl                 1,800    1,631       10.4%             7.3%      3.1%
    WW                   4,138    3,899        6.1%             4.8%      1.3%
    DIABETES CARE
    -------------
    US                     941      908        3.6%             3.6%        -
    Intl                   885      877        0.9%             2.1%     -1.2%
    WW                   1,826    1,785        2.3%             2.9%     -0.6%
    ETHICON
    -------
    US                   1,499    1,296       15.7%            15.7%        -
    Intl                 1,852    1,717        7.9%             5.3%      2.6%
    WW                   3,351    3,013       11.2%             9.7%      1.5%
    ETHICON ENDO-
     SURGERY
    -------------
    US                   1,474    1,442        2.2%             2.2%        -
    Intl                 2,027    1,794       13.0%             9.9%      3.1%
    WW                   3,501    3,236        8.2%             6.5%      1.7%
    ORTHO-
     CLINICAL
     DIAGNOSTICS
    ------------
    US                     815      846       -3.7%            -3.7%        -
    Intl                   702      616       14.0%            11.1%      2.9%
    WW                   1,517    1,462        3.8%             2.6%      1.2%
    VISION CARE
    -----------
    US                     722      703        2.7%             2.7%        -
    Intl                 1,299    1,185        9.6%             4.9%      4.7%
    WW                   2,021    1,888        7.0%             4.0%      3.0%
    TOTAL MEDICAL
     DEVICES AND
     DIAGNOSTICS
    -------------
    US                   8,551    8,194        4.4%             4.4%        -
    Intl                 9,726    9,071        7.2%             4.5%      2.7%
    WW                  18,277   17,265        5.9%             4.5%      1.4%




    (1) Operational growth excludes the effect of currency
    (2) Select areas (unaudited)
    (3) Reported in U.S. sales
    (4) Included in Other
    (5) Includes sales of Drug-Eluting Stents for Q3 2010 of $47, $89
    and $136MM Domestic, International and Worldwide respectively
          Includes sales of Drug-Eluting Stents for Q3 2009 of $53, $158 and
          $211MM Domestic, International and Worldwide respectively
          Includes sales of Drug-Eluting Stents for September YTD 2010 of
          $166, $327 and $493MM Domestic, International and Worldwide
          respectively
          Includes sales of Drug-Eluting Stents for September YTD 2009 of
          $189, $507 and $696MM Domestic, International and Worldwide
          respectively
    (6) Conforms to current presentation

SOURCE Johnson & Johnson

Copyright (C) 2010 PR Newswire. All rights reserved


Close window | Back to top

Copyright 2014 Johnson & Johnson

This site is governed solely by applicable U.S laws and governmental regulations. Please see our Privacy Policy. Use of this site constitutes your consent to application of such laws and regulations and to our Privacy Policy.Your use of the information on this site is subject to the terms of our Legal Notice. You should view the News section and the most recent SEC Filings in the Investor section in order to receive the most current information made available by Johnson & Johnson.Contact Us with any questions or search this site for more information.